These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9542765)

  • 21. Designing a low-cost drug resistance database for viral hepatitis.
    Kuiken C
    Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
    Shakya N; Vedi S; Liang C; Agrawal B; Tyrrell DL; Kumar R
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6475-80. PubMed ID: 22985854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parenterally transmitted hepatitis: viruses, vaccines, and antiviral therapy.
    Chung RT; Kaplan LM
    Compr Ther; 1993; 19(4):163-73. PubMed ID: 7505215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.
    Masgala A; Bonovas S; Nikolopoulos GK
    Mini Rev Med Chem; 2012 Aug; 12(9):890-904. PubMed ID: 22530578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and current management of hepatitis B and C in China.
    Sun YT; Zhang YX; Tang H; Mao Q; Wang XZ; Zhang LY; Chen H; Zhong YN; Lin SM; Zhang DZ
    World J Gastroenterol; 2014 Oct; 20(37):13582-90. PubMed ID: 25309089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis.
    Boettler T; Moradpour D; Thimme R; Zoulim F
    J Hepatol; 2014 Sep; 61(3):696-705. PubMed ID: 24845610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.
    von Hahn T; Steinmann E; Ciesek S; Pietschmann T
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):63-79. PubMed ID: 20136590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cytokines and hepatitis].
    Degos F
    Rev Prat; 1993 Mar; 43(5):569-73. PubMed ID: 7688135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Turning hepatitis C into a real virus.
    Murray CL; Rice CM
    Annu Rev Microbiol; 2011; 65():307-27. PubMed ID: 21682640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.
    Tanikawa K
    Curr Pharm Des; 2006; 12(11):1371-7. PubMed ID: 16611121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents.
    Wedemeyer H; Jensen DM; Godofsky E; Mani N; Pawlotsky JM; Miller V;
    Hepatology; 2012 Dec; 56(6):2398-403. PubMed ID: 22707382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleotide prodrugs for HCV therapy.
    Sofia MJ
    Antivir Chem Chemother; 2011 Aug; 22(1):23-49. PubMed ID: 21860070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties.
    McGuigan C; Gilles A; Madela K; Aljarah M; Holl S; Jones S; Vernachio J; Hutchins J; Ames B; Bryant KD; Gorovits E; Ganguly B; Hunley D; Hall A; Kolykhalov A; Liu Y; Muhammad J; Raja N; Walters R; Wang J; Chamberlain S; Henson G
    J Med Chem; 2010 Jul; 53(13):4949-57. PubMed ID: 20527890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-based and animal models for hepatitis B and C viruses.
    Schinazi RF; Ilan E; Black PL; Yao X; Dagan S
    Antivir Chem Chemother; 1999 May; 10(3):99-114. PubMed ID: 10431609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B and C.
    Karnsakul W; Schwarz KB
    Pediatr Clin North Am; 2017 Jun; 64(3):641-658. PubMed ID: 28502443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacoeconomic appraisal of therapies for hepatitis B and C.
    Younossi ZM; Temple ME; Shermock KM
    Expert Opin Pharmacother; 2001 Feb; 2(2):205-11. PubMed ID: 11336580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the diagnosis and treatment of hepatitis B.
    Alazawi W; Foster GR
    Curr Opin Infect Dis; 2008 Oct; 21(5):508-15. PubMed ID: 18725801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.
    Jia H; Rai D; Zhan P; Chen X; Jiang X; Liu X
    Future Med Chem; 2015; 7(5):587-607. PubMed ID: 25921400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral hepatitis in older adults.
    Marcus EL; Tur-Kaspa R
    J Am Geriatr Soc; 1997 Jun; 45(6):755-63. PubMed ID: 9180674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.